Press Release: WaveEdge Capital Serves as Exclusive M&A Advisor to Seraplex on Its Sale to Prairie Capital

Dow Jones
Yesterday

WaveEdge Capital LLC, an independent healthcare and life sciences investment bank, served as exclusive sell-side M&A advisor to Seraplex (the "Company"), a California specialty blood products company, in connection with its sale to Prairie Capital.

SAN MATEO, Calif., Oct. 1, 2026 /PRNewswire/ -- WaveEdge Capital LLC ("WaveEdge"), an independent healthcare and life sciences investment bank, served as exclusive sell-side M&A advisor to Seraplex, a California specialty blood products company in connection with its sale to Prairie Capital ("Prairie"). "We are pleased to have worked with these stellar teams to complete a transaction with such potential for future growth. In addition, the integration of Seraplex with a consortium of Prairie biospecimen companies has resulted in a formidable suite of products and services supporting the biopharmaceutical and diagnostic industries", said Rose Maljanian, Managing Director, WaveEdge.

Seraplex has served prestigious, global diagnostic and therapeutic manufacturing companies for over five decades. The Company has diversified beyond normal specimens to specialty and disease state products, maintaining their commitment to high-quality product and excellent customer service. The demand for their products continues to rise as precision medicine, biomarker discovery and new therapeutic development continues to outpace market expectations.

About Prairie Capital:

Headquartered in Chicago, Illinois, Prairie Capital is a private equity firm focused on guiding high-potential, founder-owned companies on the journey to becoming scalable platforms prepared for accelerated growth. The firm is a multi-sector investor with dedicated industry teams that leverage lessons learned from decades of private equity investing experience.

For more information on the company and/or any add-on acquisition opportunities, please contact:

Mike Praljak at mpraljak@prairie-capital.com

Sean McNally at smcnally@prairie-capital.com

About WaveEdge Capital:

WaveEdge is an independent investment bank providing experienced M&A advisory services to lower middle market companies across the healthcare and life sciences space. Areas of specialization include single- and multi-specialty physician practices; outsourced provider services; outsourced pharmaceutical and diagnostic products and services; digital health; and behavioral health. WaveEdge's deal team was led by Rose Maljanian and John Selig.

For more information, visit www.waveedgecap.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client's experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the mergers & acquisitions industry and the strength of the healthcare sector of the U.S. economy, and the ability to attract and retain qualified employees.

Media Contact

John Selig

WaveEdge Capital LLC

1.415.577.7783

john.selig@waveedgecap.com

https://www.waveedgecap.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/waveedge-capital-serves-as-exclusive-ma-advisor-to-seraplex-on-its-sale-to-prairie-capital-302895015.html

SOURCE WaveEdge Capital LLC

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10